- Kinsenoside
-
- $63.00 / 1mg
-
2026-01-12
- CAS:151870-74-5
- Min. Order:
- Purity: 99.86%
- Supply Ability: 10g
- Kinsenoside
-
- $0.00 / 20mg
-
2023-02-24
- CAS:151870-74-5
- Min. Order: 20mg
- Purity: ≥98%(HPLC)
- Supply Ability: 10 g
|
| | Kinsenoside Basic information |
| Product Name: | Kinsenoside | | Synonyms: | Kinsenoside;(4R)-4-(beta-D-Glucopyranosyloxy)dihydro-2(3H)-furanone;2(3H)-Furanone, 4-(β-D-glucopyranosyloxy)dihydro-, (4R)-;(4R)-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-one;(+)-Kinsenoside;Keap1-Nrf2,Inhibitor,pulposus,disc,degeneration,Kinsenoside,inhibit,cells,nucleus,Nrf2,Apoptosis,intervertebral;(R)-4-(((2R,3R,4S,5S,6R)-3,4,5-Trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)dihydrofuran-2(3H)-one | | CAS: | 151870-74-5 | | MF: | C10H16O8 | | MW: | 264.23 | | EINECS: | | | Product Categories: | | | Mol File: | 151870-74-5.mol |  |
| | Kinsenoside Chemical Properties |
| Boiling point | 570.2±50.0 °C(Predicted) | | density | 1.59±0.1 g/cm3(Predicted) | | storage temp. | 4°C, protect from light | | solubility | DMF:14.0(Max Conc. mg/mL);52.98(Max Conc. mM)
DMSO:33.0(Max Conc. mg/mL);124.89(Max Conc. mM)
PBS (pH 7.2):10.0(Max Conc. mg/mL);37.85(Max Conc. mM) | | form | A crystalline solid | | pka | 12.81±0.70(Predicted) | | color | White to light yellow | | InChI | InChI=1/C10H16O8/c11-2-5-7(13)8(14)9(15)10(18-5)17-4-1-6(12)16-3-4/h4-5,7-11,13-15H,1-3H2/t4-,5-,7-,8+,9-,10-/s3 | | InChIKey | MQEPWBMWFIVRPS-MUOXDHKLNA-N | | SMILES | O1C[C@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)CC1=O |&1:2,4,6,9,11,13,r| |
| | Kinsenoside Usage And Synthesis |
| Description | Kinsenoside is a glycoside originally isolated from A. formosanus that has diverse biological activities, including antihyperlipidemic, immunosuppressive, and anti-inflammatory properties. It increases lipolysis mediated by adipose triglyceride lipase and increases hydrolysis of triglycerides in C3H10T1/2 adipocytes. It also increases phosphorylation of peroxisome proliferator-activated receptor α (PPARα) and CREB as well as protein levels of SIRT1, PGC-1α, and carnitine palmitoyltransferase I. Kinsenoside downregulates the expression and phosphorylation of VEGF receptor 2 (VEGFR2) and inhibits crosstalk between the JAK2/STAT3 and PI3K/AKT signaling pathways in dendritic cells in vitro. It decreases the production of IFN-γ, IL-17, and TNF-α and increases the production of IL-10 in splenocytes isolated from mice with collagen-induced arthritis (CIA). Kinsenoside (300 mg/kg per day) decreases the expression of IL-1β, TNF-α, and matrix metalloproteinase-9 (MMP-9) and increases the expression of IL-10 in inflamed joints in a mouse model of collagen-induced arthritis and prevents paw edema and reduces the severity of arthritis. | | Uses | Kinsenoside is an anti-hyperlipidemic agent isolated from the plant Anoect chilus. | | Definition | ChEBI: (3R)-5-Oxotetrahydro-3-furanyl beta-D-glucopyranoside is a glycoside. | | in vivo | Kinsenoside (10 mg/kg; ip; every 3 days for 4 weeks) promotes the expression of Nrf2 and ameliorates intervertebral disc degeneration (IDD) induced by Pentobarbital (50 mg/kg) in vivo in rat model[1].
Kinsenoside (100 mg/kg, 300 mg/kg; ip; 1 h before LPS induction) inhibits LPS (40 mg/kg; ip)-induced inflammatory model in mice[3].
| | References | [1] X M DU. Glycosidic constituents from in vitro Anoectochilus formosanus.[J]. Chemical & pharmaceutical bulletin, 2000, 48 11: 1803-1804. DOI: 10.1248/cpb.48.1803
[2] De Souza, F.I., Zumiotti, A.V., and Da Silva, C.F. Neuregulins 1-α and 1-β on the regeneration the peripheral nerves[J]. Acta Ortop Bras.
[3] HUNG-BO HSIAO. Kinsenoside inhibits the inflammatory mediator release in a type-II collagen induced arthritis mouse model by regulating the T cells responses[J]. BMC Complementary and Alternative Medicine, 2016, 16 1. DOI: 10.1186/s12906-016-1054-8
[4] MING XIANG. Effects of kinsenoside, a potential immunosuppressive drug for autoimmune hepatitis, on dendritic cells/CD8+T cells communication in mice[J]. Hepatology, 2016, 64 6: 2135-2150. DOI: 10.1002/hep.28825 |
| | Kinsenoside Preparation Products And Raw materials |
|